ITEMS IN AFP WITH KEYWORD:
R.K. is a 52-year-old white man who presents to your office for a preventive health visit. He is overweight and has a history of hypertension and hyperlipidemia, which are stable and well controlled with medication. One of his coworkers was recently diagnosed with obstructive sleep apnea (OSA), and ...
Jul 15, 2017 Issue
Screening for Obstructive Sleep Apnea in Adults: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for obstructive sleep apnea (OSA) in asymptomatic adults.
Get the latest evidence to help choose between benzodiazepines, z-drugs, melatonin agonists, tricyclic antidepressants, antihistamines, atypical antipsychotics, suvorexant, and antiepileptics.
The American Academy of Pediatrics (AAP) updated its recommendations to reduce the risk of SIDS and suffocation, asphyxia, and entrapment associated with sleep, focusing on SUIDs that transpire during sleep in infants one year or younger.
Patients with this relatively uncommon form of insomnia have a marked propensity to underestimate sleep duration and overestimate wakefulness relative to polysomnographic measures.
May 15, 2017 Issue
Treatment of Chronic Insomnia in Adults: ACP Guideline [Practice Guidelines]
The American College of Physicians (ACP) has provided recommendations for treatment of chronic insomnia in adults. Treatment, which can include psychological or pharmacologic therapy, alone or combined, as well as complementary and alternative methods, is aimed at improving sleep, distress, and dysfunction.
Compared with usual care, the use of CPAP provides a modest improvement in daytime sleepiness, but does not reduce the likelihood of cardiovascular events, even in a high-risk population.
Loud snoring, gasping during sleep, morning headache, and daytime sleepiness can predict sleep apnea. Learn which sleep study is the diagnostic standard, and which positive airway pressure therapy is first-line treatment.
Suvorexant effectively increases total sleep time and decreases time to sleep onset. Because of its risk of abuse, significant incidence of next-day impairment, and high cost, it should be reserved for use in patients for whom other insomnia therapies, such as cognitive behavior therapy and lifestyle changes, have failed.
A five-component approach to changing patients' beliefs and behaviors surrounding sleep is effective, at least in the short term, in getting persons to fall asleep and stay asleep, although total sleep time is not increased.